Haemonetics Corporation

NYSE:HAE Voorraadrapport

Marktkapitalisatie: US$4.3b

Haemonetics Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Haemonetics heeft een totaal eigen vermogen van $878.9M en een totale schuld van $1.2B, wat de schuld-eigenvermogensverhouding op 139.6% brengt. De totale activa en totale passiva bedragen respectievelijk $2.5B en $1.6B. De EBIT Haemonetics is $213.2M waardoor de rentedekking 14.1 is. Het heeft contanten en kortetermijnbeleggingen van $300.0M.

Belangrijke informatie

139.6%

Verhouding schuld/eigen vermogen

US$1.23b

Schuld

Rente dekkingsratio14.1x
ContantUS$300.03m
AandelenUS$878.85m
Totaal verplichtingenUS$1.65b
Totaal activaUS$2.53b

Recente financiële gezondheidsupdates

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $955.9M ) HAE } overtreffen de korte termijn passiva ( $273.9M ).

Langlopende schulden: De kortetermijnactiva van HAE ( $955.9M ) dekken de langetermijnschulden ( $1.4B ) niet.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 105.4% ) HAE wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van HAE is de afgelopen 5 jaar gestegen van 65.3% naar 139.6%.

Schuldendekking: De schuld van HAE wordt niet goed gedekt door de operationele kasstroom ( 6.9% ).

Rentedekking: De rentebetalingen op de schuld van HAE worden goed gedekt door EBIT ( 14.1 x dekking).


Balans


Ontdek gezonde bedrijven